Events

John Connolly is Managing Director of York Medtech Partners, a medtech incubator based in Toronto, and a Founder and VP Corporate Development of Rna Diagnostics Inc. John has spent 15 years as a venture investor and startup entrepreneur in the Canadian medtech industry.

John will describe the founding of Rna Diagnostics, its success to date and the challenges it faces as it brings its game-changing RNA Disruption Assay™ technology to market.

Rna Diagnostics Inc. has developed a real-time cancer chemotherapy guidance tool. Less than 25% of breast cancer chemotherapy patients derive survival benefit from chemotherapy. All patients endure toxic effects. Reduction of unnecessary chemotherapy is a top priority for breast cancer specialists. The RNA Disruption Assay (RDA™) is the only diagnostic tool that measures, early in treatment, how a patient is responding to chemotherapy. Administered during the first three cycles, RDA™ measures chemotherapy effectiveness. Effective therapy is confirmed for responding patients, while non-responders may be switched from chemotherapy to alternate therapies, thereby sparing them toxic side effects. RDA™ improves patient outcomes while lowering breast cancer treatment costs.

Part of the MaRS Future of Medicine™ Series